Superbugs & Superdrugs 2019

SMi Group’s Annual Superbugs & Superdrugs conference will take place 18-19 March, 2019 in London, UK.

This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.

Highlighted session topics and focus areas include:

• Development of a pipeline of lysins for infections caused by multidrug-resistant gram-negative bacteria
• Anti-infective research: funding, filing and finance
• Developing target product profiles for priority pathogens
• How to mobilize private investors for antibiotic drug development
• Wellcome Trust: funding opportunities for anti-infective research
• Considerations for beta-lactams paired with beta-lactamase inhibitors
• A unique combination antibiotic therapy at Helperby
• Ridinilazole for the treatment of C. difficile
• Developing new therapies for fungal infection
• Pharmacodynamics to accelerate antimicrobial drug development for AMR
• Opportunities and challenges involved in pre-clinical development of novel immunotherapies
• Evaluations in prophylaxis and treatment murine models of pneumocystis pneumonia

To register visit www.superbugssuperdrugs.com/globalbiodefence

Global Biodefense in an official media partner of Superbugs & Superdrugs 2019.